The endometrium of late pregnant guinea-pigs was found to contain mRNA for relaxin. Poly(A)+RNA hybridized to 32P-labelled porcine relaxin-specific oligonucleotide probes. These probes corresponded to the C-peptide region of the prohormone. There was no hybridization to a 32P-labelled probe to the B-chain of porcine relaxin even under conditions of low stringency. The size of the relaxin mRNA was approximately 1.0 kb and similar to that found for relaxin mRNA from the pregnant sow ovary. This is the first study on relaxin mRNA from a uterine source.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1677/joe.0.118r009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pharmacokinetics Integrated With Network Pharmacology to Investigate the Potential Mechanism of Lu-Jiao Fang Inhibited Endothelial-to-Mesenchymal Transition in Pressure Overload-Induced Cardiac Fibrosis.
Biomed Chromatogr
February 2025
Department of Pharmacy, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
The aim of this study was to investigate the potential mechanism of Lu-Jiao Fang (LJF) inhibiting endothelial-to-mesenchymal transition (EndMT) in pressure overload-induced cardiac fibrosis. Pharmacokinetic behaviors of the ingredients of LJF were evaluated by LC-MS/MS analysis. Then putative pathways by which LJF regulates EndMT were analyzed by network pharmacology and verified in transverse aortic constriction-induced cardiac fibrosis rats.
View Article and Find Full Text PDFLocalisation of the relaxin-family peptide 3 receptor to enteroendocrine cells of the intestine in RXFP3-Cre/tdTomato mice.
Biochem Pharmacol
December 2024
Faculty of Health, School of Medicine, Institute for Mental and Physical Health and Clinical Translation (IMPACT), Deakin University, Waurn Ponds, Victoria 3216, Australia.
The relaxin-family peptide 3 receptor (RXFP3) and its native ligand, relaxin-3, are expressed in specific populations of brain neurons, and research on this system has focused on its role in the central nervous system. However, some studies have indicated that relaxin-3 and RXFP3 are also expressed in peripheral organs, including the gut. In this study, we characterised the identity of RXFP3-expressing cells in the gastrointestinal tract, using RXFP3-Cre/tdTomato reporter mice.
View Article and Find Full Text PDFYiqi Yangxue formula inhibits cartilage degeneration in knee osteoarthritis by regulating LncRNA-UFC1/miR-34a/MMP-13 axis.
J Ethnopharmacol
January 2025
The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, 310000, China; School of Basic Medical Sciences, Yunnan University of Chinese Medicine, Kunming, 650500, China. Electronic address:
Article Synopsis
- Knee osteoarthritis (KOA) is a common and debilitating condition, and the Yiqi Yangxue formula (YQYXF) is often used to treat it, though research on its epigenetic effects and role of non-coding RNA is limited.
- The study investigates how YQYXF impacts the long chain non-coding RNA UFC1, miR-34a, and matrix metalloproteinase-13 (MMP-13), looking at their interactions and significance in KOA.
- Using various methods including UHPLC-QE-MS technology and RT-PCR, researchers found that YQYXF contains key compounds like flavonoids and phenylpropanoids that potentially influence the expression of genes related to
Relaxin-2 promotes osteoblastic differentiation mediated by epidermal growth factor and epidermal growth factor receptor signaling.
Biotechnol Appl Biochem
September 2024
Department of Hand, Foot, and Orthopedics Surgery, Weifang People's Hospital, Weifang, Shandong Province, China.
Loss of osteogenic differentiation potential of osteoblasts has been associated with the pathogenesis of osteoporosis. Thus, stimulation of osteoblastic differentiation is a therapeutic strategy for osteoporosis. Relaxin-2 is a peptide hormone with potent biological functions.
View Article and Find Full Text PDFTranslational pharmacokinetic/pharmacodynamic model for mRNA-0184, an investigational therapeutic for the treatment of heart failure.
Clin Transl Sci
August 2024
Moderna, Inc., Cambridge, Massachusetts, USA.
Heart failure (HF) is a complex, progressive disorder that is associated with substantial morbidity and mortality on a global scale. Relaxin-2 is a naturally occurring hormone that may have potential therapeutic benefit for patients with HF. To investigate the therapeutic potential of relaxin in the treatment of patients with HF, mRNA-0184, a novel, investigational, lipid nanoparticle (LNP)-encapsulated mRNA therapy that encodes for human relaxin-2 fused to variable light chain kappa (Rel2-vlk) was developed.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!